Foghorn Therapeutics Inc. (FHTX)
NASDAQ: FHTX · Real-Time Price · USD
4.680
-0.080 (-1.68%)
May 4, 2026, 4:00 PM EDT - Market closed
Foghorn Therapeutics Employees
Foghorn Therapeutics had 106 employees as of December 31, 2025. The number of employees decreased by 6 or -5.36% compared to the previous year.
Employees
106
Change (1Y)
-6
Growth (1Y)
-5.36%
Revenue / Employee
$291,594
Profits / Employee
-$700,783
Market Cap
274.72M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 106 | -6 | -5.36% |
| Dec 31, 2024 | 112 | -4 | -3.45% |
| Dec 31, 2023 | 116 | -45 | -27.95% |
| Dec 31, 2022 | 161 | 42 | 35.29% |
| Dec 31, 2021 | 119 | 24 | 25.26% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Cellectis | 229 |
| LENZ Therapeutics | 152 |
| Coherus Oncology | 147 |
| Zentalis Pharmaceuticals | 106 |
| C4 Therapeutics | 104 |
| Artiva Biotherapeutics | 104 |
| Editas Medicine | 87 |
| Protara Therapeutics | 46 |
FHTX News
- 13 days ago - Foghorn Therapeutics Presents New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and for Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting - GlobeNewsWire
- 25 days ago - Foghorn Therapeutics to Present New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting - GlobeNewsWire
- 7 weeks ago - Foghorn Therapeutics Provides Financial Update for 2025 and 2026 Strategic Outlook - GlobeNewsWire
- 2 months ago - Foghorn Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference - Transcripts
- 2 months ago - Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Ryan Maynard as Chief Financial Officer - GlobeNewsWire
- 2 months ago - Foghorn Therapeutics Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026 - Transcripts
- 3 months ago - Foghorn Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit - GlobeNewsWire